Clinical Trial Search

Primary: Particpants Who Achieve and Maintain the Systolic Blood Pressure Goals for Each Treatment Tier. — 18; 20; 22; 7 participants — p=< 0.01

Primary: Median Time to Achieve Target SBP Range (≤160 mmHg to ≥140 mmHg) Within 30 Minutes of Initiation of Clevidipine — 5.5 minutes

Primary: Change in CBF From Baseline (Before Start of the Hemodialysis Study Session), at 20 Minutes, and at the End of the Hemodialysis Study Session, Measured by [15O]H2OPET-CT…

Primary: Number of Participants With Clinically Significant Cardiac Events — 3; 0; 0 Participants — p=0.0427

Primary: A Composite of Death or Dependency, With Dependency Being Defined by a Score of 3 to 5 on the Modified Rankin Scale (mRS) — 719; 785 participants

Primary: Number of Study Subjects With Life-threatening Thromboembolic Complications — 1; 0; 0 Participants — p=1.00

Primary: Change in Interleukin-1beta Level in Blood (Picogram/Milliliter)

Primary: Resting Cerebral Blood Flow During Peak Period of Vasospasm Risk — .34; .30 mL/100 g/min

Primary: Global Disability (Functional Outcome) Assessed Via the Ordinal Modified Rankin Score (mRS) — 32; 20; 4; 2 Participants

Primary: Percentage of Patients With mRS 0-3 — 39; 27 Participants

Primary: Change From Baseline to Day 2 in Cerebrovascular Reactivity as Measured by the Slope (Amplitude Over Time to Peak) From Visual Task-evoked Functional Magnetic Resonance…

Primary: Rate of Recurrent Symptomatic Hemorrhage During the Two Year Follow-up Period in Patients With CASH. — 10; 11 Number of new bleeds

Primary: Composite Neurological Outcome of Clinical Stroke or New Ischemic Brain Lesion on Diffusion Weighted MRI or Neurocognitive Dysfunction 4 to 6 Weeks After Surgery. — 79…

Primary: Depression — 12.33; 6 units on a scale

Primary: Patient Tolerance of Conivaptan — 0; 0; 1; 0 Participants

Primary: Change in Oxygen Delivery in Vulnerable Brain Regions — 3.7; 4.3 ml/100g/min — p=0.001

Primary: Change in Platelet Activity, Measured in Seconds on PFA-EPI Assay, From Pre to Post-treatment — 68 seconds — p=0.014

Primary: Clot Specimen Histology — 373; 12 Count of specimen

Primary: Number of Patients With Serious Device-related Adverse Events — 0 Participants

Primary: Number of Participants With Reperfusion Injury Hemorrhagic Transformation — 3 participants

Primary: Proportion of Patients With Modified Rankin Scale (mRS) Score 0-2 at 90 Days — 48; 47 Participants

Primary: Absolute Perihematoma Edema (aPHE) Volume Measured by Computed Tomography (CT) Scan After Intracerebral Hemorrhage (ICH) — 55.09; 52.50 mL — p=0.585

Primary: Dichotomized, Adjudicated Modified Rankin Scale Score 0-3 vs. 4-6 at 365 Days Post Ictus (Adjusted) — 110; 100; 139; 140 Participants — p=0.73

Primary: Mean Blood Flow Velocity in Middle Cerebral Artery — 63.7; 61.8 cm/s — p=0.554

Primary: Safety Outcome Number 1: Rate of Mortality — 9.5; 14.8; 7.1 percentage of participants — p=0.324

Primary: Glasgow Outcome Scale — 17; 17; 34; 37 participants — p=.01

Primary: Cerebral Artery Vasospasm — 16; 7 Participants

Primary: Mean Change in Cisternal Blood From Enrollment to Catheter Removal — -64.7 percent change

Primary: Sleep Apnea Diagnosis Rate — 58; 5 participants

Primary: Infrascanner 2500™ Diagnostic Performance — 79; 65; 27; 9 Participants